You're signed outSign in or to get full access.
Venbio Partners LLC
venBio Partners LLC is a life sciences investment firm focused on biotech, medical devices, and broader life sciences sectors, investing in innovative life science, biotech, and pharma companies.
Investment Strategy
Invests in early and late-stage biotechnology, life sciences, biopharmaceutical, and pharma companies, focusing on novel therapeutics for unmet medical needs.
Latest 13F Filing Activity
Venbio Partners LLC filed their most recent 13F report on Jun 30, 2025 disclosing 6 equity positions with a total 13F market value of $115M. The fund increased holdings in Pharvaris N V, Lyell Immunopharma Inc., Harmony Biosciences HLDGS in among other positions. Venbio Partners LLC reduced exposure to Acelyrin Inc., Lyell Immunopharma Inc., Alumis Inc. among others.
Top Holdings
Equity Positions (6)
| Ticker | Security | Weight | Market Value | Shares | Avg Cost | Price | Change (QoQ) |
|---|---|---|---|---|---|---|---|
P PHVS | PHARVARIS N V | 65.78% | $75.5M | 4,289,304 | $22.81 | $17.60 | +$8.1M |
H HRMY | HARMONY BIOSCIENCES HLDGS IN | 13.47% | $15.5M | 489,194 | $33.90 | $31.60 | -$777.8K |
A ALMS | ALUMIS INC | 12.08% | $13.9M | 4,619,803 | $8.76 | $3.00 | -$3.3M |
L LYEL | LYELL IMMUNOPHARMA INC | 3.65% | $4.2M | 473,479 | $8.84 | $8.84 | +$4.2M |
A ALXO | ALX ONCOLOGY HLDGS INC | 3.51% | $4.0M | 9,699,925 | $37.74 | $0.42 | -$2.0M |
Industry Allocation
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more